Core Viewpoint - Foresight Autonomous Holdings Ltd. is advancing its collaboration with SoftBank Corp. to validate Eye-Net's V2X collision prediction and prevention technology, aiming to enhance road safety and operational efficiency through real-time location information exchange among road users [1][2][3] Group 1: Collaboration Details - The collaboration builds on positive results from a previous proof-of-concept project with SoftBank, focusing on tailoring the solution to meet SoftBank's specific needs and evaluating its potential for new market introductions [2] - The initiative emphasizes a shared commitment to accelerating the deployment of connected mobility solutions, which is expected to improve situational awareness and reduce traffic-related incidents in Japan and beyond [3] Group 2: Company Overview - Eye-Net develops next-generation V2X collision prevention solutions and smart automotive systems aimed at enhancing road safety and situational awareness for all road users in urban environments, utilizing advanced AI technology and existing cellular networks for real-time pre-collision alerts [4] - Foresight Autonomous Holdings Ltd. is a technology company focused on developing advanced 3D perception and cellular-based applications through its subsidiaries, including Eye-Net Mobile Ltd., which specializes in both "in-line-of-sight" and "beyond-line-of-sight" accident-prevention solutions [6][7]

Geneva, Switzerland, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that it is redefining vertical integration in the quantum era by building a platform where trust begins, in silicon. Rather than developing quantum solutions in isolated layers of hardware, software, or connectivity, SEALSQ has designed a fully integrated arc ...

Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch ...

Core Insights - Ernexa Therapeutics has been selected as one of ten companies globally to participate in the Japan Entry Acceleration Program (JEAP), highlighting its innovative cell therapy platform for advanced cancer and autoimmune diseases [1][2]. Group 1: Company Overview - Ernexa Therapeutics focuses on developing novel cell therapies, particularly using induced pluripotent stem cells (iPSCs) to create allogeneic synthetic induced mesenchymal stem cells (iMSCs), which provide scalable treatment solutions [7]. - The company’s lead products include ERNA-101, aimed at enhancing the immune system's ability to target tumors, and ERNA-201, which addresses harmful inflammation in autoimmune diseases [5][8]. Group 2: Program Participation - JEAP is a competitive initiative by the Japan External Trade Organization (JETRO), attracting around 70 companies from 25 countries, emphasizing the high level of competition [2][6]. - Participation in JEAP offers Ernexa access to expert mentoring, market-entry guidance, and opportunities for collaboration with leading Japanese research and development organizations [4][6]. Group 3: Strategic Goals - The program is expected to advance Ernexa's pipeline in Japan, with ERNA-101 entering first-in-human clinical trials for ovarian cancer this year, addressing significant unmet needs in cancer treatment [5]. - The company aims to leverage JEAP to explore strategic partnerships and clinical development opportunities, ultimately striving to deliver hope to patients with serious conditions [3].

Core Insights - OMNIQ Corp has been contracted to provide license plate recognition (LPR) solutions for a major technology innovator, enhancing mobility across large campus sites [1][2] - The deployment of OMNIQ's LPR technology aims to create a more efficient and secure mobility experience across multiple campuses [3] - The project reflects a collaboration between OMNIQ's research and development teams and the customer's leadership to create a tailored solution for the customer's complex campus environment [4] Company Overview - OMNIQ Corp specializes in AI-based computer vision and data intelligence, offering solutions for various applications including supply chain management, public safety, and traffic management [6][7] - The company provides a range of services including hardware, software, and automated management services, supported by a highly experienced team [8] - OMNIQ engages with several billion-dollar markets that are experiencing double-digit growth, such as the Global Safe City market and the Ticketless Safe Parking market [9] Technology and Solutions - The LPR solution includes the mobile AI-based license plate inventory system (MLPI), which provides real-time visibility across large and complex sites [3] - The campuses will utilize permission-based parking zones to manage access for thousands of employees and visitors, enhancing operational insight and consistency [3] - OMNIQ's solutions are designed with strict privacy and data protection standards, ensuring that data is processed securely and used only for authorized purposes [10]

Core Insights - Atos has been recognized as a Leader in the ISG Provider Lens for AI-Driven Application Managed Services and Application Development Outsourcing, highlighting its position in the European market [1][2] Group 1: Leadership and Recognition - The assessment evaluated 29 service providers, with Atos sharing the top Leader ranking alongside Accenture, Capgemini, and Deloitte [2] - Atos' leadership is attributed to its AI-enabled modernization capabilities tailored for regulated industries, emphasizing a customer-centric and compliance-focused approach [4][6] Group 2: Technological Advancements - The report emphasizes the integration of the Atos Polaris AI Platform, which enhances service delivery through modules for development, support, testing, and modernization [3][5] - Atos is recognized for its advanced GenAI frameworks that facilitate secure and sustainable adoption of AI technologies within complex delivery pipelines [5][7] Group 3: Strategic Focus - The company’s strategy includes leveraging sovereign cloud architectures and responsible AI principles to ensure compliance and security in its offerings [6][7] - Atos combines application management stability with embedded AI for automation and predictive analytics, ensuring operational continuity and cost control in enterprise environments [7] Group 4: Company Overview - Atos Group operates with approximately 63,000 employees and generates annual revenue of around €8 billion, focusing on digital transformation across 61 countries [9] - The company is a leader in cybersecurity, cloud, and high-performance computing, committed to providing tailored AI-powered solutions for various industries [9]

Core Insights - Propanc Biopharma, Inc. has filed its fourth new provisional patent application in two months, focusing on innovative formulations of pancreatic proenzymes, which are critical for addressing challenges in stability and transport for biomedical applications [1][2] - The company aims to double its intellectual property portfolio from approximately 90 to over 200 patents, covering various aspects of its proenzyme technology, which targets and prevents metastasis from solid tumors [2][3] - Propanc's lead asset, PRP, is designed to selectively attack cancer stem cells and circulating tumor cells while sparing healthy tissue, offering a potential long-term therapy with reduced toxicity compared to conventional treatments [3][4] Company Developments - The recent patent applications are part of a strategy to secure leadership in a field with significant unmet medical needs, particularly for aggressive cancers with limited treatment options [2][3] - Preparations for a Phase 1b First-In-Human study of PRP in advanced cancer patients are advancing rapidly, with expectations for further updates on the clinical pathway and broader pipeline soon [3] Industry Context - Propanc is developing a novel approach to cancer treatment by targeting cancer stem cells through proenzyme activation, which addresses the underlying drivers of cancer proliferation and spread [4]

TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- HUB Cyber Security Ltd. (Nasdaq: HUBC) (“HUB” or the “Company”), a global leader in confidential computing and secured data fabric technologies, today announced that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is currently not in compliance with Nasdaq Listing Rule 5550(b)(2), which requires the Company to maintain a minimum Market Value of Listed Securities of US$35 million (“MVLS”) for continued listing ...

Core Insights - ParaZero Technologies Ltd. has signed a new reseller agreement with a prominent Western European partner, including an initial purchase order for DefendAir training kits, marking a strategic expansion in NATO-aligned defense markets [1][2][3] Group 1: Company Developments - The new reseller partnership builds on ParaZero's recent successes, including a strategic distribution agreement and live demonstrations of the DefendAir platform for NATO officers [2] - DefendAir is a rapidly deployable, net-based counter-UAS system designed to neutralize hostile drones in various environments, including battlefield and urban settings [2][3] - The training kits will facilitate comprehensive operator training and tactical deployment simulations, enhancing operational capability and adoption [3] Group 2: Market Position and Strategy - The momentum in Europe indicates a growing demand for reliable counter-drone technologies amid evolving security challenges [3] - ParaZero aims to strengthen partnerships that enhance airspace security for allied forces and critical assets, contributing to collective defense efforts against aerial threats [4] - The company positions itself as a trusted provider of advanced C-UAS solutions to NATO members and partners [4]

Core Viewpoint - GCM Grosvenor will release its fourth quarter and full year 2025 results on February 10, 2026, and will host a conference call to discuss these results and provide a business update [1][2]. Group 1: Company Overview - GCM Grosvenor is a global alternative asset management solutions provider with approximately $87 billion in assets under management across various investment strategies including private equity, infrastructure, real estate, credit, and absolute return [3]. - The firm has over 50 years of experience in alternatives and aims to deliver value for clients through its cross-asset class and flexible investment platform [3]. Group 2: Team and Global Presence - GCM Grosvenor employs around 560 professionals and serves a diverse global client base consisting of institutional and individual investors [4]. - The company is headquartered in Chicago and has offices in major cities including New York, Toronto, London, Frankfurt, Tokyo, Hong Kong, Seoul, and Sydney [4].